Immunocytokines

Main Content

Overview

Modakafusp alfa is a first-in-class antibody–cytokine fusion protein (immunocytokine) consisting of a human IgG1 and a cytokine engineered to target CD38, indicated for the treatment of relapsed/refractory multiple myeloma.

Article

Initial results in RRMM with modakafusp alfa: a first-in-class CD38-targeted immunocytokine

April 14, 2022

Categories

• Relapsed/refractory multiple myeloma: Learn more

Therapeutics

Types of Therapeutics

• Antibody recruiting molecules

  • BHV-1100

• Antibody therapy

  • Daratumumab
  • Denosumab

• BCL-2 inhibitors

  • Venetoclax

• Biological therapy

  • Anakinra

• Biphosphonates

  • Clodronate

• Checkpoint inhibitors

  • Atezolizumab

• Proteasome inhibitors

  • Bortezomib

• T-cell engagers

  • Blinatumomab

• Vaccines

  • PVX-410